real-time news and commentary for investors
Friday, Aug 30
Teva's Nuvigil misses primary enpoint in major depression/ bipolar trial
- Teva (TEVA +0.6%) releases top-line results from a Phase 3 study of armodafinilin in major depression associated with bipolar I disorder.
- The study did not meet the primary endpoint of determining "whether armodafinil treatment (150mg per day) is more effective than placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics."
- The company says it will not go forward with regulatory filings for "armodafinil" in this indication.
- TEVA did say that while it was clearly "disappointed" in the results, there will be no material impact to the company. (PR)